Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
Abstract Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases. As gut microbial imbalances and maladaptive host responses have b...
Guardado en:
Autores principales: | Mette Simone Aae Madsen, Jacob Bak Holm, Albert Pallejà, Pernille Wismann, Katrine Fabricius, Kristoffer Rigbolt, Martin Mikkelsen, Morten Sommer, Jacob Jelsing, Henrik Bjørn Nielsen, Niels Vrang, Henrik H. Hansen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7cc76709e4214ac29b3c51f8c12f05a0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Ben Jones, et al.
Publicado: (2018) -
Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee W Chia, et al.
Publicado: (2009) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010) -
Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms
por: Shunsuke Kato, et al.
Publicado: (2021)